Liver Function Tests of COVID-19 Patients
Keywords:Coronavirus, COVID-19, Length of hospitalization
Objectives: This study aimed to evaluate liver injuries in hospitalized COVID-19 patients.
Methods: This was a prospective study. Patients who were admitted to Vasi Hospital of Sabzevar University of Medical Sciences between April 2019 and September 2019 had a definite laboratory diagnosis of COVID-19. Enzymes and parameters of ALT, AST, ALP, total and direct bilirubin, and recovery status. The respiratory rate at admission was considered an outcome of COVID-19 severity.
Results: Total number of 100 patients (50 male/50 female), with a mean age of 54±18.01 years (ranging from 18 to 86 units/liter) were evaluated. Respiratory rate was significantly associated with direct bilirubin (r=0.433; P<0.001), with a positive correlation. Other findings were non-significant (P>0.05). Thirty-two patients had a partial recovery, 49 had a complete recovery and eighteen percent died. There was no statistically significant relationship between the condition of the COVID-19 patients and the levels of total bilirubin, direct bilirubin, Alkaline Phosphatase (ALP), serum glutamic-oxaloacetic transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT) (P>0.05). The results of the independent t-test showed that in patients whose respiratory rate was less than 20 or higher than 20, male or female patients, and less than 5 or more than 5 days hospitalization, there were no statistically significant differences in the amount of bilirubin, direct bilirubin, ALP, SGOT, SGPT (P>0.05).
Conclusion: Only direct bilirubin was positively correlated with respiratory rates and no other comparisons were significant. Patients with true dyspnea should be assessed more closely.
Sabzevar University of Medical Sciences
Conflicts of interest:
AT and MG wrote the study protocol, collected datasets, performed statistical analyses, and wrote the manuscript.
The study was approved by the Institutional Review Board of Sabzevar University of Medical Sciences with the code IR.MEDSAB.REC.1399.118
1. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct 22;586(7830):516-27.
2. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nature reviews microbiology. 2022 May;20(5):270-84.
3. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, Yang B, Chen Z. An overview of COVID-19. Journal of Zhejiang University. Science. B. 2020 May;21(5):343.
4. Greer N, Bart B, Billington CJ, Diem SJ, Ensrud KE, Kaka A, Klein M, Melzer AC, Reule S, Shaukat A, Sheets K. COVID-19 postacute care major organ damage: a systematic review. BMJ open. 2022 Aug 1;12(8):e061245.
5. Skok K, Stelzl E, Trauner M, Kessler HH, Lax SF. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Archiv. 2021 Feb;478:343-53.
6. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Current problems in cardiology. 2020 Aug 1;45(8):100618.
7. Idalsoaga F, Ayares G, Arab JP, Díaz LA. COVID-19 and indirect liver injury: a narrative synthesis of the evidence. Journal of Clinical and Translational Hepatology. 2021 Oct 10;9(5):760.
8. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. Journal of molecular histology. 2020 Dec;51:613-28.
9. Lizardo-Thiebaud MJ, Cervantes-Alvarez E, Limon-De La Rosa N, Tejeda-Dominguez F, Palacios-Jimenez M, Mendez-Guerrero O, Delaye-Martinez M, Rodriguez-Alvarez F, Romero-Morales B, Liu WH, Huang CA. Direct or collateral liver damage in SARS-CoV-2–infected patients. InSeminars in Liver Disease 2020 Aug (Vol. 40, No. 03, pp. 321-330). Thieme Medical Publishers.
10. La Hoz RM, Mufti AR, Vagefi PA. Short‐term liver transplant outcomes from SARS‐CoV‐2 lower respiratory tract NAT positive donors. Transplant Infectious Disease. 2022 Feb;24(1):e13757.
11. Wanner N, Andrieux G, Badia-i-Mompel P, Edler C, Pfefferle S, Lindenmeyer MT, Schmidt-Lauber C, Czogalla J, Wong MN, Okabayashi Y, Braun F. Molecular consequences of SARS-CoV-2 liver tropism. Nature Metabolism. 2022 Mar;4(3):310-9.
12. Bugra A, Das T, Arslan MN, Ziyade N, Buyuk Y. Postmortem pathological changes in extrapulmonary organs in SARS-CoV-2 rt-PCR–positive cases: a single-center experience. Irish Journal of Medical Science (1971-). 2022 Feb;191(1):81-91.
13. Reddy KR. SARS‐CoV‐2 and the liver: considerations in hepatitis B and hepatitis C infections. Clinical Liver Disease. 2020 May 21;15(5):191-4.
14. Yu R, Tan S, Dan Y, Lu Y, Zhang J, Tan Z, He X, Xiang X, Zhou Y, Guo Y, Deng G. Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection. Virology. 2021 Jan 15;553:131-4.
15. Bramante CT, Tignanelli CJ, Dutta N, Jones E, Tamaritz L, Clark J, Melton-Meaux G, Usher M, Ikramuddin S. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. MedRxiv. 2020 Sep 2.
16. Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: A multi-center research network study. Gastroenterology. 2020 May 3
17. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical features of COVID-19-related liver damage. Clinical Gastroenterology and Hepatology. 2020 Apr 10
18. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y. COVID-19: Abnormal liver function tests. Journal of Hepatology. 2020 Apr 13.
19. Respiratory rate was significantly associated with direct bilirubin (r=0.433; P<0.001), with a positive correlation.
20. Altaf A, Abbas Z, Mandviwalla HA, Qadeer MA, Siyal M, Tariq M, Ghafoor A, Karamat M, Shahid B, Ali M. Severe COVID-19 associated with liver injury in patients without preexisting liver disease. Cureus. 2021 Apr 26;13(4).
How to Cite
Copyright (c) 2023 Copyright (c) 2022 Updates in Emergency Medicine Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.